ADC Therapeutics SA (NYSE:ADCT) Q1 2024 Earnings Call Transcript May 6, 2024 ADC Therapeutics SA reports earnings inline with expectations. Reported EPS is $-0.56 EPS, expectations were $-0.56. ADCT isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and […]
LAUSANNE, Switzerland, May 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it has agreed to sell, by way of an underwritten offering, 13,411,912 of its common shares at a price of $4.900 per share and, to certain investors who so choose in lieu of common shares, pre-funded warrants to purchase 8,163,265 common shares at a price of $4.812 per pre-funded warrant (being the offering price per common share in the offering minus the exercise price). The gross procee
ADC Therapeutics (ADCT) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?